Your session is about to expire
← Back to Search
Combination Therapy: PY314 + Pembrolizumab for Breast Cancer
Study Summary
This trial is testing a new drug called PY314 for people with cancer that has spread or come back and is not responding to other treatments.
- Breast Cancer
- Lung Adenocarcinoma
- Kidney Cancer
- Gynecologic Cancers
- Solid Tumors
- Colorectal Cancer
- Ovarian Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your condition must be getting worse, as confirmed by medical records.You have brain metastases (cancer that has spread to the brain), but they have been stable and not causing any symptoms for at least 3 months.You have not received any cancer treatment within the past three weeks before starting the study drug.You are eligible for a type of treatment that targets specific molecules in your body.You have advanced lung cancer that has not responded well to chemotherapy or immunotherapy treatments.
- Group 1: Part B: Combination dose expansion cohort 2
- Group 2: Part A: PY314 Single agent dose level 1
- Group 3: Part A: PY314 Single agent dose level 2
- Group 4: Part A: Combination dose level 1
- Group 5: Part B: Single agent dose expansion dose level 1
- Group 6: Part B: Combination dose expansion cohort 5
- Group 7: Part A: PY314 Single agent dose level 3
- Group 8: Part A: Combination dose level 4
- Group 9: Part B: Combination dose expansion cohort 3
- Group 10: Part B: Combination dose expansion cohort 1
- Group 11: Part A: PY314 Single agent dose level 4
- Group 12: Part A: Combination dose level 2
- Group 13: Part A: Combination dose level 3
- Group 14: Part B: Combination dose expansion cohort 4
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what condition does the PY314 + Pembrolizumab combination remedy typically apply?
"For individuals suffering from malignant tumors, inoperable melanoma, and high microsatellite instability levels, Combination Therapy: PY314 + Pembrolizumab can provide relief."
Has the amalgamation of PY314 and pembrolizumab been authorized by the FDA?
"The safety of Combination Therapy: PY314 + Pembrolizumab was rated 1 out of 3 due to the limited clinical data backing its efficacy and lack of evidence for long-term safety."
How many Canadian facilities are currently administering this investigation?
"There are 27 sites hosting this medical trial, such as Vanderbilt Ingram Cancer Center in Nashville, Sarah Cannon Research Institute in Duarte and City of Hope - Comprehensive Cancer Centre in Boston. In addition to these locations there are 24 more offering the same service."
Are there any precedential investigations examining the effects of PY314 and pembrolizumab in tandem?
"The combination of PY314 and pembrolizumab therapy was initially trialled at City of Hope back in 2010. Since then, 249 medical trials have been finished with a further 961 active trials currently running, many taking place right here in Nashville."
What aims is this clinical trial attempting to attain?
"Over the duration of 36 months, this medical study will be monitoring Dose Limiting Toxicity (DLT) of PY314. Secondary objectives include Clinical Benefit Rate (CBR), Measure PY314 Volume at Steady State (Vss), and determining time to maximum concentration during Cycle 1 (Tmax)."
How many individuals are participating in the trial of this experimental treatment?
"To perform this medical trial, Gilead Sciences requires 288 patients who meet the eligibility criteria. The sponsor will be conducting the study at numerous sites, such as Vanderbilt Ingram Cancer Center in Nashville and Sarah Cannon Research Institute in Duarte."
Is there still availability for participants in this experiment?
"Indeed, the trial is actively seeking participants as per information hosted on clinicaltrials.gov. It was originally published in October of 2020 and has been updated recently on September 1st 2022 to reflect its search for 288 patients over 27 individual sites."
Share this study with friends
Copy Link
Messenger